Research programme: DNA interference therapies - Sierra Oncology

Drug Profile

Research programme: DNA interference therapies - Sierra Oncology

Alternative Names: PNT 100; PNT 200; PNT 300; PNT 400; PNT 500; PNT 600

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProNAi Therapeutics
  • Developer Sierra Oncology
  • Class Oligonucleotides
  • Mechanism of Action BIRC5 protein modulators; DNA modulators; KRAS protein modulators; Proto-oncogene protein c-bcl-2 modulators; STAT3 transcription factor modulators; Transforming growth factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Jan 2017 ProNAi Therapeutics is now called Sierra Oncology
  • 03 Nov 2015 Marina Biotech has patent protection for SMARTICLES® delivery technology and for the composition of NOV 340 in Canada
  • 10 Jun 2015 Marina Biotech receives patent allowance for SMARTICLES® formulation in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top